Work

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

Year: 2021

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-020-01035-9

Authors: J. Wu, D. Liu, M. Offin, C. Lezcano, J. M. Torrisi, S. Brownstein, D. M. Hyman, M. M. Gounder, W. Abida, A. Drilon, J. J. Harding, R. J. Sullivan, F. Janku, D. Welsch, M. Varterasian, A. Groover, B. T. Li, M. E. Lacouture

Institutions: Memorial Sloan Kettering Cancer Center, Chang Gung University, Chang Gung Memorial Hospital, Keelung Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, Weill Cornell Medicine, Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W3120597036

FWCI: 3.834

Cites: 61

Cited by: 30

Related to: 10